Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Matisse obtains FDA Fast Track Designation for isupartob sodium in sepsis. FDA's Fast Track is designed to get important new drugs to the patient earlier.
-
Matisse Pharmaceuticals announces U.S. FDA clearance of the company’s Investigational New Drug (IND) application for isupartob sodium
-
Matisse Pharmaceuticals receives INN (International Non-proprietary Name) isupartob sodium from the WHO recognizing first-in-class drug status for M6229.
-
Successful phase 1 with prolonged infusion duration could offer an effective solution for irreversibly stopping harmful inflammatory responses in sepsis.